Modified recombinant human endostatin and uses thereof
AssigneesJiangsu Simcere Pharmaceutical R&D Co., Ltd., Shandong Xiansheng Maidejin Biological Pharmaceutical Co., Ltd.
InventorsWenbing Yao, Hong Tian, Xiangyang Xu, Hairui Li, Yue Dong, Xiangdong Gao
Life of this patent
Estimating the term…
Abstract
Provided is a kind of modified recombinant human endostatin that has the structure of CH3O—(CH2CH2O)m—CH2CH2CH2—NαH-Endostar, wherein the average molecular weight of CH3O—(CH2CH2O)m—CH2CH2CH2— is 20-40 kD. The modified recombinant human endostatin enhances the stability in vivo, improves blood drug concentration, prolongs half-life, markedly increases the activity of inhibiting the endothelial cells proliferation, thus reduces drug dosage and decreases administration frequency. Its application for preparing anti-tumor pharmaceutical compositions is also provided.
Claims1
A modified recombinant endostatin, having a structure of:
- CH3O—(CH2CH2O)m—CH2CH2CH2—NαH-Endostar,
- wherein a weight average molecular weight of CH3O—(CH2CH2O)m—CH2CH2CH2— is 40 kD;
- and wherein an amino acid sequence of said Endostar is selected from the group consisting of SEQ ID NO:
- 1 and SEQ ID NO:
- 2, wherein the in vivo half-life of the modified recombinant endostatin is 97 h.
Dependencies are inferred from the claim text.